Executive Summary, and Coherent Opportunity Map (COM)
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics, Regulations, and
Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and
Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST
Analysis
• Global Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Regions
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Competition by Manufacturers
including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales
Area and Product Type.
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Manufacturers Profiles/Analysis
including Company Basic Information, Manufacturing Base and Its Competitors.
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Manufacturing Cost Analysis
including Key Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast including Production,
Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
North America is expected to hold a dominant position in the market, increasing focus of
manufacturers on novel drug development for ALS
North America is expected to hold a dominant position in the amyotrophic lateral sclerosis
treatment market, as major companies present in the region are focusing on collaborations for
product development. For instance, in January 2018 Sangamo Therapeutics, Inc. and Pfizer Inc.
collaborated for the development of a potential gene therapy using zinc finger protein
transcription factors (ZFP-TFs) for the treatment of ALS. Companies based in emerging
economies of Asia Pacific are focusing on developing novel drugs for treatment of ALS. For
instant major companies such as Mitsubishi Tanabe Pharma Corporation and Takeda
Pharmaceutical Company Ltd are developing drugs for treatment of ALS.
Major players operating in the global amyotrophic lateral sclerosis treatment market include
Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan
Pharmaceuticals Inc.